Related Experiment Video
Updated: Sep 19, 2025

Isolation of Exosomes from the Plasma of HIV-1 Positive Individuals
Published on: January 5, 2016
Medications for opioid use disorder shape immune responses during chronic HIV infection
Jack A Collora1, Savannah F Steinhauser1, Timothy C Davenport1
1Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT 06519, USA.
Abstract:
People living with HIV (PLWHs) have higher risk of opioid use disorder (OUD). Whether medications for opioid use disorder (MOUDs) change immune responses in HIV infection is unknown. We examined the immune profiles in PLWHs before and 3 months after initiation of the μ opioid receptor agonist methadone, partial agonist buprenorphine, and antagonist naltrexone. Using single-cell DOGMA-seq, we profiled 29,462 peripheral blood immune cells in 12 PLWHs. We found that naltrexone treatment increased type I interferon (IFN) responses while buprenorphine increased tumor necrosis factor (TNF) responses in cytotoxic T cell population. We found that HIV+ cells in PLWHs with OUD upregulated PTPN13 and TAF5L, both of which are associated with HIV replication. We found trends suggesting increased HIV RNA expression after methadone and decreased HIV RNA expression after buprenorphine and naltrexone initiation. Overall, PLWHs treated with MOUD had improved immune responses and decreased HIV expression.
Insights
Medications for opioid use disorder (MOUDs) impact immune responses in people living with HIV (PLWHs). Naltrexone and buprenorphine improved immune function and decreased HIV expression in a small study.
Area of Science:
- Immunology
- Infectious Diseases
- Pharmacology
Background:
- People living with HIV (PLWHs) have a higher risk of opioid use disorder (OUD).
- The effects of medications for opioid use disorder (MOUDs) on immune responses in PLWHs are not well understood.
Purpose of the Study:
- To investigate how different MOUDs (methadone, buprenorphine, naltrexone) affect immune profiles in PLWHs with OUD.
- To assess changes in HIV expression in response to MOUD initiation.
Main Methods:
- Single-cell DOGMA-seq was used to profile 29,462 peripheral blood immune cells from 12 PLWHs.
- Immune cell profiles were analyzed before and 3 months after initiating methadone, buprenorphine, or naltrexone.
Main Results:
- Naltrexone increased type I interferon (IFN) responses, while buprenorphine increased tumor necrosis factor (TNF) responses in cytotoxic T cells.
- HIV+ cells upregulated PTPN13 and TAF5L, genes associated with HIV replication.
- Methadone showed a trend towards increased HIV RNA expression, whereas buprenorphine and naltrexone showed a trend towards decreased HIV RNA expression.
Conclusions:
- MOUDs can modulate immune responses in PLWHs.
- Buprenorphine and naltrexone may offer benefits by improving immune responses and reducing HIV expression.
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Retrovirus Life Cycles
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioid Analgesics: Morphine and Other Natural Cogeners
Analgesia and Pain Management

